search
Back to results

Paclitaxel Coated Balloon Catheter for Prevention of Restenosis in Femoropopliteal Arteries (PACCOCATH_F)

Primary Purpose

Peripheral Arterial Disease

Status
Completed
Phase
Phase 1
Locations
Germany
Study Type
Interventional
Intervention
paclitaxel coated balloon catheter (device with drug)
Sponsored by
University Hospital, Saarland
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Peripheral Arterial Disease focused on measuring restenosis, peripheral arterial disease, paccocath, drug-coated balloon

Eligibility Criteria

18 Years - 95 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Rutherford stage 1, 2, 3, 4 oder 5
  • Occlusion or Stenosis of Superficial femoral and/or popliteal artery
  • Successful guide wire passage of the lesion
  • Patient suitable of vascular surgery in case of complication
  • Written consent
  • Patient is willing to take part in follow up examinations within the study

Exclusion Criteria:

  • Acute ischemia
  • Distal run off less than one vessel
  • Pregnancy
  • Hyperthyroidism
  • Thrombocytes <100.000/mm3 or >700.000/mm3, Leucocytes <3.000/mm3
  • Life expectancy less than two years
  • Patients not willing to enter the study

Sites / Locations

  • Klinik für Strahlenheilkunde, Charité Campus Virchow Klinikum
  • Institut für Diagnostische Radiologie und Neuroradiologie, Universitätsklinikum Greifswald der Ernst-Moritz-Arndt-Universität

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Active Comparator

Arm Label

1

2

Arm Description

PTA

PTA with Paccocath

Outcomes

Primary Outcome Measures

angiographic late lumen loss

Secondary Outcome Measures

binary restenosis rate; major adverse events

Full Information

First Posted
May 10, 2007
Last Updated
June 29, 2010
Sponsor
University Hospital, Saarland
search

1. Study Identification

Unique Protocol Identification Number
NCT00472472
Brief Title
Paclitaxel Coated Balloon Catheter for Prevention of Restenosis in Femoropopliteal Arteries
Acronym
PACCOCATH_F
Official Title
Paclitaxel Coated Balloon Catheter for Inhibition of Restenosis in Femoropopliteal Arteries (PACCOCATH - FEM I)
Study Type
Interventional

2. Study Status

Record Verification Date
May 2007
Overall Recruitment Status
Completed
Study Start Date
April 2004 (undefined)
Primary Completion Date
July 2007 (Actual)
Study Completion Date
July 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
University Hospital, Saarland

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The PACCOCATH FEM study is a randomized, double-blinded German multicenter trial on the efficacy and tolerance of a paclitaxel coated balloon catheter in prevention of restenosis after femoropopliteal angioplasty.
Detailed Description
Background: Treatment of patients with peripheral arterial disease (PAD) in the femoropopliteal arteries by percutaneous intervention is still limited by high rates of restenosis. The aim of the present study is to evaluate the efficacy and safety of a novel method of short time local drug delivery based on a paclitaxel-coated balloon in femoropopliteal arteries. Methods and results: The double-blind and randomized study enrolled n=79 patients with occlusion or stenosis of femoropopliteal arteries. Inclusion criteria were clinical Rutherford stage 1-5, occlusion or hemodynamic relevant stenosis (≥ 70 % diameter) of femoropopliteal arteries and successful guiding wire recanalization. The primary endpoint was the late lumen loss after 6 months follow-up as seen in angiography. Secondary endpoints included the rate of restenosis (a binary variable), change of ankle brachial index (ABI), rutherford class and major adverse events.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Arterial Disease
Keywords
restenosis, peripheral arterial disease, paccocath, drug-coated balloon

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
87 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Placebo Comparator
Arm Description
PTA
Arm Title
2
Arm Type
Active Comparator
Arm Description
PTA with Paccocath
Intervention Type
Device
Intervention Name(s)
paclitaxel coated balloon catheter (device with drug)
Intervention Description
PTA vs Paccocath
Primary Outcome Measure Information:
Title
angiographic late lumen loss
Time Frame
6 months
Secondary Outcome Measure Information:
Title
binary restenosis rate; major adverse events
Time Frame
18 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
95 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Rutherford stage 1, 2, 3, 4 oder 5 Occlusion or Stenosis of Superficial femoral and/or popliteal artery Successful guide wire passage of the lesion Patient suitable of vascular surgery in case of complication Written consent Patient is willing to take part in follow up examinations within the study Exclusion Criteria: Acute ischemia Distal run off less than one vessel Pregnancy Hyperthyroidism Thrombocytes <100.000/mm3 or >700.000/mm3, Leucocytes <3.000/mm3 Life expectancy less than two years Patients not willing to enter the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jens Ricke, MD
Organizational Affiliation
Klinik für Strahlenheilkunde, Charité Campus Virchow, Augustenburger Platz 1, 13353 Berlin, Germany
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ulrich Speck, PhD
Organizational Affiliation
Radiologie, Campus Mitte, Charite, 10117 Berlin, Germany
Official's Role
Study Director
Facility Information:
Facility Name
Klinik für Strahlenheilkunde, Charité Campus Virchow Klinikum
City
Berlin
ZIP/Postal Code
13353
Country
Germany
Facility Name
Institut für Diagnostische Radiologie und Neuroradiologie, Universitätsklinikum Greifswald der Ernst-Moritz-Arndt-Universität
City
Greifswald
ZIP/Postal Code
17487
Country
Germany

12. IPD Sharing Statement

Citations:
PubMed Identifier
15302790
Citation
Scheller B, Speck U, Abramjuk C, Bernhardt U, Bohm M, Nickenig G. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation. 2004 Aug 17;110(7):810-4. doi: 10.1161/01.CIR.0000138929.71660.E0. Epub 2004 Aug 9.
Results Reference
background
PubMed Identifier
15076010
Citation
Speck U, Scheller B, Abramjuk C, Grossmann S, Mahnkopf D, Simon O. Inhibition of restenosis in stented porcine coronary arteries: uptake of Paclitaxel from angiographic contrast media. Invest Radiol. 2004 Mar;39(3):182-6. doi: 10.1097/01.rli.0000116125.96544.64.
Results Reference
background
PubMed Identifier
14563585
Citation
Scheller B, Speck U, Schmitt A, Bohm M, Nickenig G. Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol. 2003 Oct 15;42(8):1415-20. doi: 10.1016/s0735-1097(03)01056-8.
Results Reference
background
PubMed Identifier
12909076
Citation
Scheller B, Speck U, Romeike B, Schmitt A, Sovak M, Bohm M, Stoll HP. Contrast media as carriers for local drug delivery. Successful inhibition of neointimal proliferation in the porcine coronary stent model. Eur Heart J. 2003 Aug;24(15):1462-7. doi: 10.1016/s0195-668x(03)00317-8.
Results Reference
background
PubMed Identifier
17435062
Citation
Scheller B, Speck U, Bohm M. Prevention of restenosis: is angioplasty the answer? Heart. 2007 May;93(5):539-41. doi: 10.1136/hrt.2007.118059.
Results Reference
background
PubMed Identifier
17101615
Citation
Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Bohm M, Speck U. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006 Nov 16;355(20):2113-24. doi: 10.1056/NEJMoa061254. Epub 2006 Nov 13.
Results Reference
background
PubMed Identifier
16864669
Citation
Speck U, Scheller B, Abramjuk C, Breitwieser C, Dobberstein J, Boehm M, Hamm B. Neointima inhibition: comparison of effectiveness of non-stent-based local drug delivery and a drug-eluting stent in porcine coronary arteries. Radiology. 2006 Aug;240(2):411-8. doi: 10.1148/radiol.2402051248.
Results Reference
background
PubMed Identifier
18779447
Citation
Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, Dietz U, Hosten N, Hamm B, Speck U, Ricke J. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008 Sep 23;118(13):1358-65. doi: 10.1161/CIRCULATIONAHA.107.735985. Epub 2008 Sep 8. Erratum In: Circulation. 2008 Oct 14;118(16):e670.
Results Reference
derived

Learn more about this trial

Paclitaxel Coated Balloon Catheter for Prevention of Restenosis in Femoropopliteal Arteries

We'll reach out to this number within 24 hrs